NCT04144582

Sintilimab Combined With Docetaxel for Standard Chemotherapy Failure Non-driver Gene Mutation Metastatic Non-small Cell Lung Cancer

Multiple-center, Single-arm, Phase II Study on Sintilimab Combined With Docetaxel in Non-driver Gene Mutation Advanced NSCLC Patients Who Had Failed With Double Platinum-based Chemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Yongchang Zhang · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety and effectiveness of Sintilimab Combined With Docetaxel in Non-driver Gene Mutation NSCLC patients who failed with double platinum-based chemotherapy

Conditions

• Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Sintilimab Combined With Docetaxel Monotherapy	Sintilimab 200mg i.v q3w , Docetaxel 75mg/m2 i.v q3w

Timeline

• Start date: 2019-01-01
• Primary completion: 2020-09-30
• Completion: 2021-12-31
• First posted: 2019-10-30
• Last updated: 2022-03-02

Locations

2 sites across 1 country: China